share_log

HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target

HC Wainwright & Co.重申對Astria Therapeutics的買入,維持20美元的目標股價
Benzinga ·  2023/05/12 06:30

HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $20 price target.

HC Wainwright & Co. 分析師約瑟夫·潘吉尼斯重申了Astria Therapeutics(納斯達克股票代碼:ATXS)的買入並維持20美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論